logo
Boeing beats Wall Street's expectations with 2nd quarter rise in revenue

Boeing beats Wall Street's expectations with 2nd quarter rise in revenue

Fast Company4 days ago
Boeing's second-quarter loss narrowed and revenue improved as the aircraft manufacturer delivered more commercial planes in the period.
Boeing Co. lost $611 million, or 92 cents per share, for the three months ended June 30. A year earlier it lost $1.44 billion, or $2.33 per share.
Adjusting for one-time gains, Boeing lost $1.24 per share. This was better than the loss of $1.54 per share that analysts surveyed by Zacks Investment Research expected.
Shares rose slightly before the market open on Tuesday.
Revenue climbed to $22.75 billion from $16.87 billion, mostly due to 150 commercial deliveries compared with 92 deliveries in the prior-year period.
The performance topped Wall Street's estimate of $21.86 billion.
'Our fundamental changes to strengthen safety and quality are producing improved results as we stabilize our operations and deliver higher quality airplanes, products and services to our customers,' CEO Kelly Ortberg said in a statement. 'As we look to the second half of the year, we remain focused on restoring trust and making continued progress in our recovery while operating in a dynamic global environment.'
Boeing has been dealing with a variety of issues over the past few years.
On Sunday Boeing said that it expects more than 3,200 union workers at three St. Louis-area plants that produce U.S. fighter jets to strike after they rejected a proposed contract that included a 20% wage increase over four years.
The International Machinists and Aerospace Workers union said the vote by District 837 members was overwhelmingly against the proposed contract. The existing contract was to expire at 11:59 p.m. Central time Sunday, but the union said that a 'cooling off' period would keep a strike from beginning for another week, until Aug. 4.
Last fall, Boeing offered a general wage increase of 38% over four years to end a 53-day strike by 33,000 aircraft workers producing passenger aircraft.
In June the National Transportation Safety Board said that its 17-month long investigation found that lapses in Boeing's manufacturing and safety oversight, combined with ineffective inspections and audits by the Federal Aviation Administration, led to a door plug panel flying off Alaska Airlines flight 1282, which was a Boeing 737 Max 9 aircraft, last year.
Boeing said in a statement at the time that it will review the NTSB report and will continue working on strengthening safety and quality across its operations.
The Max version of Boeing's bestselling 737 airplane has been the source of persistent troubles for the company since two of the jets crashed, one in Indonesia in 2018 and another in Ethiopia in 2019, killing a combined 346 people.
In May the Justice Department reached a deal allowing Boeing to avoid criminal prosecution for allegedly misleading U.S. regulators about the Max before the two crashes.
Boeing was also in the news last month when a 787 flown by Air India crashed shortly after takeoff and killed at least 270 people. Investigators have not determined what caused that crash, but so far they have not found any flaws with the model, which has a strong safety record.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Jim Cramer on Boeing: 'Just Call Me a Buyer of That One'
Jim Cramer on Boeing: 'Just Call Me a Buyer of That One'

Yahoo

time2 hours ago

  • Yahoo

Jim Cramer on Boeing: 'Just Call Me a Buyer of That One'

The Boeing Company (NYSE:BA) is one of the stocks Jim Cramer recently talked about. Cramer noted that the company reported a 'great quarter with beautiful cash flow,' as he commented: 'Now, I felt the same way about Boeing. Now, here's a stock that just hit a 52-week high after giving you almost a double from its low in April. Thank you, Kelly Ortberg. And even though it reported a great quarter with beautiful cash flow, the stock still got hit today. But unlike all the others, just call me a buyer of that one.' Pixabay/Public Domain Boeing (NYSE:BA) manufactures and services aerospace and defense products, including commercial jetliners, military aircraft, satellites, missile systems, and space exploration technologies. On July 21, Cramer suggested buying more of the company stock, as he said: 'Get more Boeing. Get more Boeing. They report this week. I think it's going to be a terrific quarter. Let the stock come in. If it comes in down, let's say it comes to $220, here's what you want to do: [buy, buy, buy] Pull the trigger.' While we acknowledge the potential of BA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Kansas City Life: Q2 Earnings Snapshot
Kansas City Life: Q2 Earnings Snapshot

Yahoo

time3 hours ago

  • Yahoo

Kansas City Life: Q2 Earnings Snapshot

KANSAS CITY, Mo. (AP) — KANSAS CITY, Mo. (AP) — Kansas City Life Insurance Co. (KCLI) on Friday reported a loss of $28.1 million in its second quarter. The Kansas City, Missouri-based company said it had a loss of $2.90 per share. Earnings, adjusted for non-recurring costs, were 77 cents per share. The insurance company posted revenue of $122.3 million in the period. _____ This story was generated by Automated Insights ( using data from Zacks Investment Research. Access a Zacks stock report on KCLI at Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Tempus AI Stock Before Q2 Earnings Release: To Buy or Not to Buy?
Tempus AI Stock Before Q2 Earnings Release: To Buy or Not to Buy?

Yahoo

time3 hours ago

  • Yahoo

Tempus AI Stock Before Q2 Earnings Release: To Buy or Not to Buy?

Tempus AI, Inc. TEM is scheduled to report second-quarter 2025 results on Aug. 8. In the last reported quarter, the company's adjusted loss of 24 cents was narrower than the Zacks Consensus Estimate of a loss of 27 cents per share. Tempus AI, which went public in June 2024, exceeded estimates in two of the trailing four quarters and missed in two, the average negative earnings surprise being 2.07%. The Zacks Consensus Estimate for revenues is currently pegged at $299.3 million for the second quarter, implying an 80.4% improvement over the year-ago period. The Zacks Consensus Estimate for the second-quarter bottom line has narrowed by 4 cents to a loss of 23 cents per share over the past 90 days. TEM's Earnings Estimate Revision Trend Image Source: Zacks Investment Research Throughout the second quarter of 2025, Tempus AI had an impressive run on the bourses with a 34.5% gain. Despite macroeconomic challenges, including escalating trade tensions that broadly impacted the healthcare technology sector, the company witnessed strong momentum, primarily driven by a series of strategic acquisitions and partnerships in the field of AI-driven precision medicine. During this period, the company not only surpassed the 9.3% gain posted by the broader industry but also significantly outperformed the 3.4% decline of the Medical sector. The S&P 500 benchmark index gained 10.7% during this period. The company has also outperformed other players in the health infotech field, like 10x Genomics TXG and SOPHiA GENETICS SOPH. While TXG gained 33.5%, SOPH declined 2.3% during the said period. Q2 Price Comparison Image Source: Zacks Investment Research Let's see how things have shaped up for TEM shares prior to this announcement: Key Factors to Note Prior to Tempus AI's Q2 Earnings Tempus AI recently announced a three-year, $200 million foundational model partnership with AstraZeneca AZN and Pathos, which is expected to have contributed to its second-quarter performance. This non-exclusive data licensing agreement aims to develop the world's largest foundation model in oncology using over 300 petabytes of Tempus' multimodal data. With the first version of the model expected in 9-12 months, the deal is already transforming Tempus AI's data monetization trajectory. Management confirmed that revenues from this deal will be recognized ratably over the three-year term, starting in the second quarter. Tempus AI's hereditary testing segment, which contributed meaningfully to first-quarter growth, is expected to have maintained the trend this time too. When Tempus acquired Ambry Genetics, it guided mid-to-high teens growth, but the segment exceeded expectations with a 23% unit increase. While management has been cautious about projecting ongoing acceleration, they have also expressed confidence in the long-term potential for broader hereditary screening applications, ranging from cancer to cardiovascular and neurological risk. Tempus continued to expand its diagnostics portfolio with the recent FDA clearance of ECG-Low EF, its second AI-powered ECG tool for detecting low ejection fraction, further strengthening its position in cardiology and extending its reach beyond oncology. Meanwhile, the company launched xM for TRM, a liquid biopsy assay for monitoring immunotherapy response, which showed promising early data at ASCO 2025. These likely contributed to the second-quarter top line too. Tempus AI is advancing its digital health strategy by integrating Tempus One, its GenAI clinical assistant, into EHR systems, enabling physicians to query data, access guidelines and streamline workflows. The launch of Agent Builder for custom GenAI tools further deepens its role in clinical settings. Tempus One too is expected to have witnessed strong customer adoption during the second quarter. However, despite strong top-line growth and product momentum, Tempus AI in 2025 is facing a few near-term challenges. The company remains unprofitable, with an adjusted EBITDA loss of $16.2 million in the first quarter. Though the loss narrowed year over year, it raised questions about the timeline to profitability amid ongoing R&D investments. Additionally, while the AstraZeneca-Pathos foundation model deal is significant, its revenues will be recognized ratably over three years, limiting short-term financial impact. Further, investments tied to these updates, including product development, regulatory efforts, and marketing, are likely to have pushed operating expenses higher in the second quarter, putting some pressure on short-term profitability. Broader macroeconomic factors, like tariffs, hospital budget constraints and biotech funding trends, could also affect adoption rates. Expensive Valuation TEM's stock is currently overvalued compared to its industry, as shown in the chart below. TEM is currently trading at a forward 12-month price-to-sales (P/S) ratio of 6.86, a premium to the broader industry's average of 5.80X. It also trades higher than other industry players like 10x Genomics (2.70X) and SOPHiA GENETICS (2.40X). However, the stock is trading below its one-year median of 8.00X, suggesting that it has moderated somewhat from its historical highs. Image Source: Zacks Investment Research Our Take With the AI market projected to grow exponentially in the coming years, Tempus AI is well-positioned to capitalize on expanding opportunities. With a strong financial outlook and efforts to improve healthcare outcomes, TEM presents a unique opportunity for investors seeking high returns from the AI and healthcare sectors. Yet, despite the company's several recent upsides, its premium valuation and lack of near-term profitability are limiting this Zacks Rank #3 (Hold) stock's near-term gains. While current shareholders should hold their positions, new investors should wait for the stock to retract some of its recent gains, providing a better entry point. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report AstraZeneca PLC (AZN) : Free Stock Analysis Report 10x Genomics (TXG) : Free Stock Analysis Report SOPHiA GENETICS SA (SOPH) : Free Stock Analysis Report Tempus AI, Inc. (TEM) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store